InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,003.99
(
-0.14%
)
US TECH 100
16,856.40
(
-0.47%
)
Dow Jones
37,938.76
(
0.43%
)
Brent Oil
86.68
(
0.30%
)
Bitcoin
64,558.40
(
1.66%
)
Post# of 1615
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

ListenToMe

Send PM Follow Ignore
Followers 331
Posts 33609
Boards Moderated 1
Alias Born 01/22/2005

ListenToMe

Re: None

Tuesday, 04/25/2017 3:57:11 PM

Tuesday, April 25, 2017 3:57:11 PM

Post# of 1615
LAKE ZURICH, Ill. and LAKE FOREST, Ill., April 24, 2017 – Fresenius Kabi has agreed to acquire Akorn (NASDAQ: AKRX), a U.S-based manufacturer and marketer of prescription and over-the-counter pharmaceutical products, for approximately $4.3 billion, or $34.00 a share, plus the assumption of approximately $450 million of debt1. The transaction is expected to close by early 2018 and to be accretive in 2018 to Fresenius Group net income and EPS, excluding integration costs.

1
BEAUTIFUL... :)

LET'S ALL MAKE SOME $$$$$$$

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up